The Relationship of COVID-19 with Severe Asthma Patients Treated with Biologics

Open Access

Abstract

Objective: To evaluate the relationship of COVID-19 withsevere asthma patients treated with biologics. Method:This prospective cohort study done at tertiary medicalhospital where 150 patients with severe asthma included assample. A standardised questionnaire was administered byphone or during outpatient visits and information aboutsymptoms suggestive of COVID-19, hospital admission forCOVID-19 and diagnostic testing through nasopharyngealswab (PCR) or serology (SARS-CoV-2 IgG) was obtained.During study based they divided two types of treatmentstudy group . Where patients who were treated with steroidbelong to no bilogics group, n=50 where those who aretreated with biologics, n =100. belong to Anti-IL5 or antiIL5R. Results: During the study, majority were belong to>50 years age group, 66.67% and 32% had diabetesfollowed by 23% had hypertension, 15% had Ischemicheart disease and 30% were obese. In non biologic group,10 cases had PCR positive where in other biologics group PCR positive cases were low. Inaddition during biologics usage 42% treated with Omalizumab followed by 20.69% caseswere treated with Anti-IL5, 50% treated with Mepolizumab, 17.24% treated with Reslizumaband 12.07% treated with Dupilumab. Besides that, higher number daily oral corticosteroidintake cases seen in non biologics group, 15% rather than biologics. Apart from that meanhospital stay duration or o2 therapy cases higher in non-biologics group. Conclusion: A tinynumber of COVID-19 instances were discovered within this study among adult patients withsevere asthma, none of which resulted in death or a very severe clinical course. Treatmentwith biologics for severe allergic or severe eosinophilic asthma was not linked to anincreased risk of SARS-CoV-2 infection or more severe COVID-19 infection.